证券代码：600812 股票简称：华北制药 编号：临 2026-003 华北制药股份有限公司 关于全资子公司通过药品 GMP 符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日,华北制药股份有限公司（以下简称"公司"）全资子公司华北制 药集团先泰药业有限公司（以下简称"先泰公司"）收到河北省药品监督管 理局签发的《药品 GMP 符合性检查告知书》（冀药监化药符（2026）5 号）。 现将相关信息公告如下： 一、GMP 检查相关情况 企业名称：华北制药集团先泰药业有限公司 生产地址：石家庄经济技术开发区扬子路 20 号 检查范围：无菌原料药（哌拉西林钠，802 车间冻干生产线 2 号线） 检查时间：2025 年 12 月 09 日至 2025 年 12 月 12 日 检查结论：符合《药品生产质量管理规范（2010 年修订）》及其附录 要求。 二、本次检查所涉生产线及主要产品情况 | 序号 | | 生产线名称 | | | 年生产能力 | | 主要产品 | | --- | --- | --- | --- | -- ...

华北制药公告，全资子公司华北制药集团先泰药业有限公司收到河北省药品监督管理局签发的《药品 GMP符合性检查告知书》。检查范围为无菌原料药（哌拉西林钠，802车间冻干生产线2号线），检查 时间2025年12月9日至2025年12月12日，检查结论为符合《药品生产质量管理规范（2010年修订）》及 其附录要求。802车间冻干生产线2号线年生产能力为150吨/年，主要产品为哌拉西林钠，累计投资 7457.44万元。此次检查是哌拉西林钠新增冻干生产线2号线进行注册备案后首次药品GMP符合性检查。 ...

Group 1 - The core viewpoint of the article highlights that Shijiazhuang has been recognized as the "most happy city" for two consecutive years, attributing this happiness to a conducive working environment [1] Group 2 - The foundation of a thriving business environment is illustrated through the innovation breakthroughs of companies and employees, with Huabei Pharmaceutical's employee, Han Jiachong, holding 3 patents and receiving a government reward of 20,000 yuan for his contributions [2] - Huabei Pharmaceutical has established 85 employee innovation studios, completing 338 innovation projects last year, showcasing a strong culture of innovation [2] - The Shijiazhuang Electronic Information Industry Park promotes a "sharing" model that allows companies to collaborate efficiently, with Hebei Wangxin Digital Technology Group reporting that their shared factory served over 50 small and medium-sized enterprises, generating an additional output value of over 1 billion yuan last year [2] - The sharing factory model has reduced the research and development cycle by over 15%, as noted by Hebei Gaoda Intelligent Equipment Co., which previously had to send components out for processing [2] - Small businesses in Shijiazhuang benefit from community support and networking opportunities, as expressed by local coffee and tea shop owners who appreciate the collaborative environment [2] - The overall business ecosystem in Shijiazhuang is characterized by a complete industrial chain, precise policies, and respect for every individual striving for success [2]

Core Viewpoint - The procurement process for tuberculosis drugs by the Shaanxi Provincial Center for Disease Control and Prevention has been challenged due to alleged bundling of products, limiting competition among suppliers [1][2]. Group 1: Complaint Details - The complaint was filed by North China Pharmaceutical Hebei Huanuo Co., Ltd. regarding the "tuberculosis drug procurement project," claiming that the tender documents bundled two different tuberculosis drugs, effectively restricting suppliers to those who could provide both products [1][2]. - The specific drugs in question are FDC-HR (H150mg R300mg) and FDC-HRZE (H75mg R150mg Z400mg E275mg) or FDC-HRZE (H37.5mg R75mg Z200mg E137.5mg), with only two manufacturers capable of supplying the latter, thus limiting competitive pricing [1]. Group 2: Regulatory Response - The Shaanxi Provincial Finance Department conducted a formal review of the complaint, which included written examinations and inquiries with the procurement entity and the agency involved [2]. - As a result of the review, the Finance Department mandated the procurement entity to amend the procurement documents and to initiate a new procurement process in compliance with relevant regulations [2].

Core Viewpoint - The report highlights the growth trends in China's chemical pharmaceutical raw materials industry, indicating a steady increase in production and market dynamics from 2025 to 2032 [1] Industry Summary - In November 2025, China's chemical pharmaceutical raw material production reached 331,000 tons, reflecting a year-on-year growth of 1.5% [1] - From January to November 2025, the cumulative production of chemical pharmaceutical raw materials in China was 3,358,000 tons, with a cumulative growth of 1.8% [1] - The report by Zhiyan Consulting provides insights into the supply and demand dynamics of the chemical pharmaceutical industry in China, projecting future trends from 2026 to 2032 [1] Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1]

Core Viewpoint - The antibacterial drug market in China is under pressure, with sales expected to drop below 100 billion yuan in 2024 and continue declining by approximately 18% in the first three quarters of 2025, reaching over 60 billion yuan [1][14]. Market Performance - The total sales of systemic antibacterial drugs in public medical institutions in China have been declining, with a significant drop in sales from 2024 to 2025 [1][14]. - The market for systemic antibacterial drugs includes 12 major therapeutic categories, with cephalosporins leading but experiencing four consecutive years of sales decline from 2022 to the first three quarters of 2025 [3][16]. Company Rankings - In the ranking of major companies, Pfizer, China National Pharmaceutical Group, and North China Pharmaceutical Group hold the top three positions, with sales exceeding 6.2 billion yuan, 2.1 billion yuan, and 1.9 billion yuan respectively in the first three quarters of 2025 [5][18]. - Nanjing Youke Biological, ranked fifteenth, showed remarkable growth with a year-on-year increase of 137.17%, marking its first entry into the top 20 groups [5][18]. Product Performance - The top 20 systemic antibacterial drugs accounted for over 50% of the market share, with the leading product, injectable cefoperazone/sulbactam (2:1), achieving sales of over 4.5 billion yuan [21][22]. - Notably, the compound injection of cefoperazone/sulbactam saw a dramatic increase of 219.32%, marking a significant rise in its market presence [21][23]. National Procurement Impact - Among the top 20 products, 15 have been included in the national procurement program, with 13 experiencing double-digit declines in sales [21][23]. - The tenth batch of national procurement saw injectable piperacillin/tazobactam drop by 55.61%, while the eleventh batch saw injectable cefoperazone/sulbactam decline by 47.56% [21][23]. New Drug Development - Currently, there are no domestic class 1 new drugs among the top 20 systemic antibacterial products, although five class 1 new antibacterial drugs have been approved since 2021 [25][26]. - Eight products meet the criteria for national procurement inclusion, with seven being injectable forms and one oral formulation [25][26].

Group 1 - Company announced that as of the disclosure date, the total external guarantees provided by the company and its subsidiaries amount to approximately 1.802 billion yuan, which represents 33.44% of the audited net assets attributable to ordinary shareholders for the year 2024 [1] - The company has provided guarantees totaling approximately 1.712 billion yuan for its subsidiaries, accounting for 31.77% of the audited net assets attributable to ordinary shareholders for the year 2024 [1] - The amount of guarantees provided to entities outside the consolidated financial statements is 90 million yuan, which is 1.67% of the audited net assets attributable to ordinary shareholders for the year 2024 [1] Group 2 - The news highlights a significant demand for a product, with 10,000 users placing orders for a limited stock of a high-demand item, indicating strong market interest [1] - The product was sold out quickly at a price of 1,499 yuan, demonstrating effective marketing and consumer engagement strategies [1] - The iMaotai App has reached the top of the Apple shopping chart, reflecting the popularity and successful sales strategy of the company [1]

证券代码：600812 证券简称：华北制药 公告编号：临 2026-001 | 担保对象一 | 被担保人名称 | | | 华北制药河北华民药业有限责任公司 | | --- | --- | --- | --- | --- | | | 本次担保金额 | 34,800 | 万元 | | | | 实际为其提供的担保余额 | 69,300 | 万元 | | | | 是否在前期预计额度内 | √是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | √否 | □不适用：_________ | | 担保对象二 | 被担保人名称 | | | 华北制药金坦生物技术股份有限公司 | | | 本次担保金额 | 4,975 | 万元 | | | | 实际为其提供的担保余额 | 53,889.06 | 万元 | | | | 是否在前期预计额度内 | √是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | √否 | □不适用：_________ | | 担保对象三 | 被担保人名称 | | 华北制药集团爱诺有限公司 | | | | 本次担保金额 | 12, ...

Group 1 - The application for Dapoxetine α injection by Terumo Corporation, Kofu Factory has been accepted by the National Medical Products Administration on January 5, 2026, with acceptance number JTS2600001 [1] - The drug Dapoxetine α injection is classified as a biological product and is under the import registration application type [1] - The companies involved in the application include Terumo Corporation, Kofu Factory, Kyowa Kirin Co., Ltd., and North China Pharmaceutical Jintan Biotechnology Co., Ltd. [1] Group 2 - North China Pharmaceutical Jintan Biotechnology Co., Ltd. was established on April 2, 2002, and is a medium-sized company with 619 insured employees [1] - The registered capital of North China Pharmaceutical Jintan Biotechnology Co., Ltd. is 1.85051637 billion RMB, with a paid-in capital of 1.63989152 billion RMB [1] - The major shareholder is North China Pharmaceutical Co., Ltd., holding 98% of the shares, while North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. holds 2% [1]

Core Viewpoint - The company has announced a "Quality Improvement and Efficiency Enhancement Action Plan" aimed at promoting high-quality development and enhancing investment value, particularly for small and medium-sized investors [1][3]. Group 1: Business Focus and Strategy - The company focuses on its core business of pharmaceutical product research, production, and sales, emphasizing quality and human health as its mission [1]. - The company aims to enhance operational quality by improving existing business areas and exploring new growth through innovation and collaboration [2][5]. Group 2: Shareholder Returns - The company has established a three-year shareholder return plan (2023-2025), prioritizing cash profit distribution, with a commitment to distribute at least 30% of the average annual distributable profit over the three years [3][4]. - Cumulative cash dividends over the last three accounting years amounted to 68.63 million yuan, exceeding the planned return requirements [3]. Group 3: Technological Innovation - The company has invested approximately 3.7 billion yuan in R&D since 2022, with an annual average R&D investment increase of 108.78% from 2019 to 2021 [5]. - Significant breakthroughs in technology include the approval of a new drug and multiple product launches, demonstrating the company's commitment to innovation [5][6]. Group 4: Investor Relations Management - The company emphasizes effective communication with investors through various channels, ensuring transparency and timely updates on company developments [7][8]. - Regular performance briefings and investor education activities are conducted to enhance investor understanding and protect their rights [7]. Group 5: Corporate Governance - The company adheres to relevant laws and regulations, continuously improving its governance structure and internal control systems to enhance operational standards [9][10]. - A new committee structure has been established to strengthen decision-making and oversight, ensuring fair treatment of all shareholders [10][11].